NCT01838395 - Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

March 31, 2016

Study Completion Date

July 20, 2023

Conditions

Acute Myeloid Leukemia

Interventions

DRUG

Ara-C

IV (intravenous administration)

DRUG

BL-8040

SC (subcutaneous injection)

Trial Locations (10)

Memorial Sloan-Kettering Cancer Center, New York

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore

Rambam Medical Center, Haifa

Mayo Clinic, Jacksonville

Chaim Sheba Medical Center, Ramat Gan

Washington University School of Medicine, St Louis

Tel-Aviv Sourasky Medical Center, Tel Aviv

MD Anderson Cancer Center, Houston

Shaare Zedek Medical Center, Jerusalem

Meir Medical Center, Kfar Saba